Higher susceptibility of spontaneous and NNK-induced lung neoplasms in connexin 43 deficient CD1×AJ F1 mice: Paradoxical expression of connexin 43 during lung carcinogenesis

Molecular Carcinogenesis

Volumn 52, Issue 7, 2013, Pages 497-506

  Fukumasu, Heidge ^a   Avanzo, Jose L ^a   Sanches, Daniel S ^a   Mennecier, Gregory ^a   Mori, Claudia M C ^a   Dagli, Maria L Z ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Beta catenin; Connexin 43; Lung cancer; Tobacco specific nitrosamine

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; BETA CATENIN; CONNEXIN 43;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; BETA CATENIN; BLOTTING, WESTERN; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; CONNEXIN 43; DISEASE SUSCEPTIBILITY; FEMALE; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITROSAMINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

MUS; NICOTIANA TABACUM;

EID: 84879459815     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21884     Document Type: Article

References (56)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71- 96.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137- 2150.
3. Kumar NM, Gilula NB. The gap junction communication channel. Cell 1996; 84: 381- 388.
4. Willecke K, Eiberger J, Degen J, et al. Structural and functional diversity of connexin genes in the mouse and human genome. Biol Chem 2002; 383: 725- 737.
5. Loewenstein WR, Kanno Y. Intercellular communication and the control of tissue growth: Lack of communication between cancer cells. Nature 1966; 209: 1248- 1249.
6. Mesnil M, Crespin S, Avanzo JL, Zaidan-Dagli ML. Defective gap junctional intercellular communication in the carcinogenic process. Biochim Biophys Acta 2005; 1719: 125- 145.
7. Yamasaki H, Krutovskikh V, Mesnil M, Tanaka T, Zaidan-Dagli ML, Omori Y. Role of connexin (gap junction) genes in cell growth control and carcinogenesis. C R Acad Sci III 1999; 322: 151- 159.
8. Cronier L, Crespin S, Strale PO, Defamie N, Mesnil M. Gap junctions and cancer: New functions for an old story. Antioxid Redox Signal 2009; 11: 323- 338.
9. McLachlan E, Shao Q, Laird DW. Connexins and gap junctions in mammary gland development and breast cancer progression. J Membr Biol 2007; 218: 107- 121.
10. Omori Y, Li Q, Nishikawa Y, et al. Pathological significance of intracytoplasmic connexin proteins: Implication in tumor progression. J Membr Biol 2007; 218: 73- 77.
11. Naus CC, Laird DW. Implications and challenges of connexin connections to cancer. Nat Rev Cancer 2010; 10: 435- 441.
12. Avanzo JL, Mesnil M, Hernandez-Blazquez FJ, et al. Increased susceptibility to urethane-induced lung tumors in mice with decreased expression of connexin43. Carcinogenesis 2004; 25: 1973- 1982.
13. Avanzo JL, Mennecier G, Mesnil M, et al. Deletion of a single allele of Cx43 is associated with a reduction in the gap junctional intercellular communication and increased cell proliferation of mouse lung pneumocytes type II. Cell Prolif 2007; 40: 411- 421.
14. Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: Looking to the future. J Clin Oncol 2005; 23: 3175- 3185.
15. Warner KE. The role of research in international tobacco control. Am J Public Health 2005; 95: 976- 984.
16. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003; 3: 733- 744.
17. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 1998; 11: 559- 603.
18. Hoffmann D, Brunnemann KD, Prokopczyk B, Djordjevic MV. Tobacco-specific N-nitrosamines and Areca-derived N-nitrosamines: Chemistry, biochemistry, carcinogenicity, and relevance to humans. J Toxicol Environ Health 1994; 41: 1- 52.
19. Smith TJ, Liao A, Wang LD, et al. Characterization of xenobiotic-metabolizing enzymes and nitrosamine metabolism in the human esophagus. Carcinogenesis 1998; 19: 667- 672.
20. Ziegel R, Shallop A, Jones R, Tretyakova N. K-ras gene sequence effects on the formation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-DNA adducts. Chem Res Toxicol 2003; 16: 541- 550.
21. Reaume AG, de Sousa PA, Kulkarni S, et al. Cardiac malformation in neonatal mice lacking connexin43. Science 1995; 267: 1831- 1834.
22. Nikitin AY, Alcaraz A, Anver MR, et al. Classification of proliferative pulmonary lesions of the mouse: Recommendations of the mouse models of human cancers consortium. Cancer Res 2004; 64: 2307- 2316.
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402- 408.
24. Avanzo JL, Mesnil M, Hernandez-Blazquez FJ, et al. Altered expression of connexins in urethane-induced mouse lung adenomas. Life Sci 2006; 79: 2202- 2208.
25. Kaneda M, Zhang D, Bhattacharjee R, Nakahama K, Arii S, Morita I. Vitamin K2 suppresses malignancy of HuH7 hepatoma cells via inhibition of connexin 43. Cancer Lett 2008; 263: 53- 60.
26. Zhang D, Kaneda M, Nakahama K, Arii S, Morita I. Connexin 43 expression promotes malignancy of HuH7 hepatocellular carcinoma cells via the inhibition of cell-cell communication. Cancer Lett 2007; 252: 208- 215.
27. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: Diseases and therapies. Nat Rev Genet 2004; 5: 691- 701.
28. Hecht SS, Morse MA, Amin S, et al. Rapid single-dose model for lung tumor induction in A/J mice by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and the effect of diet. Carcinogenesis 1989; 10: 1901- 1904.
29. Mesnil M, Krutovskikh V, Piccoli C, et al. Negative growth control of HeLa cells by connexin genes: Connexin species specificity. Cancer Res 1995; 55: 629- 639.
30. Yamakage K, Omori Y, Zaidan-Dagli ML, Cros MP, Yamasaki H. Induction of skin papillomas, carcinomas, and sarcomas in mice in which the connexin 43 gene is heterologously deleted. J Invest Dermatol 2000; 114: 289- 294.
31. King TJ, Lampe PD. The gap junction protein connexin32 is a mouse lung tumor suppressor. Cancer Res 2004; 64: 7191- 7196.
32. King TJ, Lampe PD. Mice deficient for the gap junction protein Connexin32 exhibit increased radiation-induced tumorigenesis associated with elevated mitogen-activated protein kinase (p44/Erk1, p42/Erk2) activation. Carcinogenesis 2004; 25: 669- 680.
33. Mitchell JA, Lye SJ. Differential activation of the connexin 43 promoter by dimers of activator protein-1 transcription factors in myometrial cells. Endocrinology 2005; 146: 2048- 2054.
34. Martin-de-Lara F, Sanchez-Aparicio P, Arias de la Fuente C, Rey-Campos J. Biological effects of FoxJ2 over-expression. Transgenic Res 2008; 17: 1131- 1141.
35. Schubert SW, Abendroth A, Kilian K, et al. bZIP-Type transcription factors CREB and OASIS bind and stimulate the promoter of the mammalian transcription factor GCMa/Gcm1 in trophoblast cells. Nucleic Acids Res 2008; 36: 3834- 3846.
36. Boogerd KJ, Wong LY, Christoffels VM, et al. Msx1 and Msx2 are functional interacting partners of T-box factors in the regulation of Connexin43. Cardiovasc Res 2008; 78: 485- 493.
37. Chen JT, Cheng YW, Chou MC, et al. The correlation between aberrant connexin 43 mRNA expression induced by promoter methylation and nodal micrometastasis in non-small cell lung cancer. Clin Cancer Res 2003; 9: 4200- 4204.
38. van der Heyden MA, Rook MB, Hermans MM, et al. Identification of connexin43 as a functional target for Wnt signalling. J Cell Sci 1998; 111: 1741- 1749.
39. Mazieres J, He B, You L, Xu Z, Jablons DM. Wnt signaling in lung cancer. Cancer Lett 2005; 222: 1- 10.
40. Xu X, Sun PL, Li JZ, Jheon S, Lee CT, Chung JH. Aberrant Wnt1/beta-catenin expression is an independent poor prognostic marker of non-small cell lung cancer after surgery. J Thorac Oncol 2011; 6: 716- 724.
41. Mak BC, Kenerson HL, Aicher LD, Barnes EA, Yeung RS. Aberrant beta-catenin signaling in tuberous sclerosis. Am J Pathol 2005; 167: 107- 116.
42. Gavert N, Ben-Ze'ev A. Beta-catenin signaling in biological control and cancer. J Cell Biochem 2007; 102: 820- 828.
43. Mennecier G, Derangeon M, Coronas V, Herve JC, Mesnil M. Aberrant expression and localization of connexin43 and connexin30 in a rat glioma cell line. Mol Carcinog 2008; 47: 391- 401.
44. de Feijter AW, Matesic DF, Ruch RJ, Guan X, Chang CC, Trosko JE. Localization and function of the connexin 43 gap-junction protein in normal and various oncogene-expressing rat liver epithelial cells. Mol Carcinog 1996; 16: 203- 212.
45. Pu P, Zhang Z, Kang C, et al. Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther 2009; 16: 351- 361.
46. Mucenski ML, Nation JM, Thitoff AR, et al. Beta-catenin regulates differentiation of respiratory epithelial cells in vivo. Am J Physiol Lung Cell Mol Physiol 2005; 289: L971- L979.
47. Udaka N, Miyagi Y, Ito T. Connexin expression in mouse lung tumor. Cancer Lett 2007; 246: 224- 229.
48. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57- 70.
49. Hokaiwado N, Asamoto M, Ogawa K, Shirai T. Transgenic disruption of gap junctional intercellular communication enhances early but not late stage hepatocarcinogenesis in the rat. Toxicol Pathol 2005; 33: 695- 701.
50. Zhai Y, Wu R, Schwartz DR, et al. Role of beta-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas. Am J Pathol 2002; 160: 1229- 1238.
51. Zhang W, DeMattia JA, Song H, Couldwell WT. Communication between malignant glioma cells and vascular endothelial cells through gap junctions. J Neurosurg 2003; 98: 846- 853.
52. Elzarrad MK, Haroon A, Willecke K, Dobrowolski R, Gillespie MN, Al-Mehdi AB. Connexin-43 upregulation in micrometastases and tumor vasculature and its role in tumor cell attachment to pulmonary endothelium. BMC Med 2008; 6: 20.
53. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004; 4: 448- 456.
54. Naus CC. Gap junctions tumour progression. Can J Physiol Pharmacol 2002; 80: 136- 141.
55. Yamasaki H, Krutovskikh V, Mesnil M, Omori Y. Connexin genes and cell growth control. Arch Toxicol Suppl 1996; 18: 105- 114.
56. Dagli ML, Hernandez-Blazquez FJ. Roles of gap junctions and connexins in non-neoplastic pathological processes in which cell proliferation is involved. J Membr Biol 2007; 218: 79- 91.